Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 7/2018

01-07-2018 | Computed Tomography

Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer

Authors: Xinzhong Zhu, Di Dong, Zhendong Chen, Mengjie Fang, Liwen Zhang, Jiangdian Song, Dongdong Yu, Yali Zang, Zhenyu Liu, Jingyun Shi, Jie Tian

Published in: European Radiology | Issue 7/2018

Login to get access

Abstract

Objectives

To distinguish squamous cell carcinoma (SCC) from lung adenocarcinoma (ADC) based on a radiomic signature

Methods

This study involved 129 patients with non-small cell lung cancer (NSCLC) (81 in the training cohort and 48 in the independent validation cohort). Approximately 485 features were extracted from a manually outlined tumor region. The LASSO logistic regression model selected the key features of a radiomic signature. Receiver operating characteristic curve and area under the curve (AUC) were used to evaluate the performance of the radiomic signature in the training and validation cohorts.

Results

Five features were selected to construct the radiomic signature for histologic subtype classification. The performance of the radiomic signature to distinguish between lung ADC and SCC in both training and validation cohorts was good, with an AUC of 0.905 (95% confidence interval [CI]: 0.838 to 0.971), sensitivity of 0.830, and specificity of 0.929. In the validation cohort, the radiomic signature showed an AUC of 0.893 (95% CI: 0.789 to 0.996), sensitivity of 0.828, and specificity of 0.900.

Conclusions

A unique radiomic signature was constructed for use as a diagnostic factor for discriminating lung ADC from SCC. Patients with NSCLC will benefit from the proposed radiomic signature.

Key points

• Machine learning can be used for auxiliary distinguish in lung cancer.
• Radiomic signature can discriminate lung ADC from SCC.
• Radiomics can help to achieve precision medical treatment.
Appendix
Available only for authorised users
Literature
1.
Printz C (2015) Lung cancer new leading cause of death for women in developed countries: Data reflects increased rates of smoking. Cancer 121:1911–1912CrossRefPubMed
2.
3.
Ferlay J, Steliarovafoucher E, Lortettieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMed
4.
Nair VS, Gevaert O, Davidzon G et al (2012) Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 72:3725–3734CrossRefPubMedPubMedCentral
5.
6.
Fukui T, Taniguchi T, Kawaguchi K et al (2015) Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma. Gen Thorac Cardiovasc Surg 63:507–513
7.
Bodendorf MO, Haas V, Laberke HG (2009) Prognostic value and therapeutic conse-quences of vascular invasion in non-small cell lung carcinoma. Lung Cancer 64:71–78CrossRefPubMed
8.
Usui S, Minami Y, Shiozawa T et al (2013) Differences in the prognostic implications of vascular invasion between lung adenocarcinoma and squamous cell carcinoma. Lung Cancer 82:407–412CrossRefPubMed
9.
Herbst RS, O'Neill VJ, Fehrenbacher L et al (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743–4750CrossRefPubMed
10.
Di Costanzo F, Mazzoni F, Micol Mela M et al (2008) Bevacizumab in non-small cell lung cancer. Drugs 68:737–746CrossRefPubMed
11.
Nguyenkim TD, Frauenfelder T, Strobel K et al (2015) Assessment of Bronchial and Pulmonary Blood Supply in Non-Small Cell Lung Cancer Subtypes Using Computed Tomography Perfusion. Investig Radiol 50:179–186
12.
Yip C, Landau D, Kozarski R et al (2014) Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology 270:141–148CrossRefPubMed
13.
Ng F, Ganeshan B, Kozarski R, Miles KA, Goh V (2013) Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology 266:177–184CrossRefPubMed
14.
Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA (2013) Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266:326–336CrossRefPubMed
15.
Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA (2010) Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 10:137–143CrossRefPubMedPubMedCentral
16.
Ganeshan B, Skogen K, Pressney I, Coutroubis D and MilesK (2012) Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 67:157-164.
17.
Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446CrossRefPubMedPubMedCentral
18.
19.
Choi ER, Lee HY, Jeong JY et al (2016) Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. Oncotarget 7:67302–67313PubMedPubMedCentral
20.
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: Images Are More than Pictures,They Are Data. Radiology 278:563–577CrossRefPubMed
21.
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRefPubMedPubMedCentral
22.
Itakura H, Achrol AS, Mitchell LA et al (2015) Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med 7:303ra138CrossRefPubMedPubMedCentral
23.
Li H, Zhu Y, Burnside ES et al (2016) MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology 281:382–391CrossRefPubMedPubMedCentral
24.
Zinn PO, Singh SK, Kotrotsou A et al (2016) 139 Clinically Applicable and Biologically Validated MRI Radiomic Test Method Predicts Glioblastoma Genomic Landscape and Survival. Neurosurgery 63:156–157CrossRef
25.
Huang Y, Liu Z, He L et al (2016) Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology 281:152234
26.
Yamamoto S, Korn RL, Oklu R et al (2014) ALK Molecular Phenotype in Non–Small Cell Lung Cancer: CT Radiogenomic Characterization. Radiology 272:568–576CrossRefPubMed
27.
Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology 264:387–396CrossRefPubMedPubMedCentral
28.
Parmar C, Lambin P, Aerts HJ et al (2015) Radiomic feature clusters and prognostic signatures specific for Lung and Head and Neck cancer. Sci Rep 5:11044CrossRefPubMedPubMedCentral
29.
Chi MA, Jian H (2016) Asymptotic properties of LASSO in high-dimensional partially linear models. Science China Mathematics 59:1–20
30.
Rao SJ (2003) Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. J Am Stat Assoc 98:257–258CrossRef
31.
Lloyd CJ (2015) Theory & Methods: Fitting Roc Curves Using Non-linear Binomial Regression. Aust. N Z J Stat 42:193–204CrossRef
32.
Ball DL, Fisher RJ, Burmeister BH et al (2013) The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 106:305–311CrossRefPubMed
33.
Khayyata S, Yun S, Pasha T et al (2009) Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 37:178–183CrossRefPubMed
34.
Montezuma D, Azevedo R, Lopes P et al (2013) A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens. Virchows Arch 463:749–754CrossRefPubMed
35.
Wang XN, Wang SJ, Pandey V et al (2015) Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma. Medicine 94:e860CrossRefPubMedPubMedCentral
36.
Patnaik S, Mallick R, Kannisto E et al (2015) MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies. J Thorac Oncol 10:446–453CrossRefPubMedPubMedCentral
37.
Ha S, Choi H, Cheon GJ et al (2014) Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result. Nucl Med Mol Imaging 48:278–286CrossRefPubMedPubMedCentral
Metadata
Title
Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer
Authors
Xinzhong Zhu
Di Dong
Zhendong Chen
Mengjie Fang
Liwen Zhang
Jiangdian Song
Dongdong Yu
Yali Zang
Zhenyu Liu
Jingyun Shi
Jie Tian
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5221-1

Other articles of this Issue 7/2018

European Radiology 7/2018 Go to the issue

Cardiac

Subclinical changes in MRI-determined right ventricular volumes and function in subjects with prediabetes and diabetes

Musculoskeletal

Early percutaneous vertebroplasty helps motorsport professionals to resume competition soon after vertebral fracture

Breast

Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour

Magnetic Resonance

Are pancreatic IPMN volumes measured on MRI images more reproducible than diameters? An assessment in a large single-institution cohort

Cardiac

Leveraging the coronary calcium scan beyond the coronary calcium score

Computed Tomography

Dual-energy CT: a phantom comparison of different platforms for abdominal imaging